Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Zenas BioPharma (NasdaqGS:ZBIO) with a Outperform recommendation.
Analyst Price Forecast Suggests 356.88% Upside
As of January 29, 2025, the average one-year price target for Zenas BioPharma is $35.09/share. The forecasts range from a low of $27.27 to a high of $47.25. The average price target represents an increase of 356.88% from its latest reported closing price of $7.68 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -3.97.
What is the Fund Sentiment?
There are 76 funds or institutions reporting positions in Zenas BioPharma. This is an increase of 70 owner(s) or 1,166.67% in the last quarter. Average portfolio weight of all funds dedicated to ZBIO is 0.75%, an increase of 55.48%. Total shares owned by institutions increased in the last three months by 1,949.90% to 25,113K shares.
What are Other Shareholders Doing?
Sr One Capital Management holds 4,912K shares representing 11.75% ownership of the company.
NEA Management Company holds 2,614K shares representing 6.25% ownership of the company.
Fairmount Funds Management holds 1,893K shares representing 4.53% ownership of the company.
NVP Associates holds 1,838K shares representing 4.40% ownership of the company.
Deerfield Management Company, L.p. holds 1,563K shares representing 3.74% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
